Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials

Journal of Diabetes and its Complications

Volumn 28, Issue 3, 2014, Pages 399-405

  Fonseca, Vivian A ^a   Devries, J Hans ^b   Henry, Robert R ^c   Donsmark, Morten ^d   Thomsen, Henrik F ^d   Plutzky, Jorge ^e  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NOVO NORDISK A S   (Denmark)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Blood pressure; Hypertension; Liraglutide; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; EXENDIN 4; GLIMEPIRIDE; INSULIN GLARGINE; LIRAGLUTIDE; PLACEBO; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; INTROSPECTION; MAJOR CLINICAL STUDY; MALE; MERCURY SPHYGMOMANOMETER; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCTION; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; META ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTOLE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; SYSTOLE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84899498561     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.01.009     Document Type: Article

References (48)

1. A.I. Adler, I.M. Stratton, H.A. Neil, J.S. Yudkin, D.R. Matthews, and C.A. Cull et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study BMJ 321 2000 412 419
2. American Diabetes Association Standards of medical care in diabetes - 2013 Diabetes Care 36 Suppl 1 2013 S11 S66
3. Amylin Pharmaceuticals, LLC Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus Available at: http://clinicaltrials.gov/show/NCT01144338 2012 [accessed 8 Aug 2013]
4. C. Arauz-Pacheco, M.A. Parrott, P. Raskin American Diabetes Association Treatment of hypertension in adults with diabetes Diabetes Care 26 Suppl 1 2003 S80 S82
5. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
6. A. Basu, N. Charkoudian, W. Schrage, R.A. Rizza, R. Basu, and M.J. Joyner Beneficial effects of GLP-1 on endothelial function in humans: Dampening by glyburide but not by glimepiride American Journal of Physiology. Endocrinology and Metabolism 293 2007 E1289 E1295
7. TM) Trial: Rationale and study design Diabetes 59 Suppl 1 2011 2303-PO
8. J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, and J.H. Brett et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
9. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
10. Data on file, Novo Nordisk.
11. Eli Lilly and Company Researching cardiovascular events with a weekly incretin in diabetes (REWIND) Available at: http://clinicaltrials.gov/show/ NCT01394952 2013 [accessed 8 Aug 2013]
12. V. Fonseca, A. Falahati, M. Zychma, S. Madsbad, and J. Plutzky A meta-analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure Diabetologia 52 Suppl 1 2009 S299
13. V. Fonseca, S. Madsbad, Falahati, M.J. Zychma, and J. Plutzky Once-daily human GLP-1 analog liraglutide reduces systolic BP - A meta-analysis of 6 Clinical Trials Diabetes 58 Suppl 1 2009 A146
14. P. Gaede, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes New England Journal of Medicine 358 2008 580 591
15. B. Gallwitz, A. Vaag, A. Falahati, and S. Madsbad Adding liraglutide to oral antidiabetic drug therapy: Onset of treatment effects over time International Journal of Clinical Practice 64 2010 267 276
16. A. Garber, R. Henry, R. Ratner, P.A. Garcia-Hernandez, H. Rodriguez-Pattzi, and I. Olvera-Alvarez et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
17. T. Gaspari, H. Liu, I. Welungoda, Y. Hu, R.E. Widdop, and L.B. Knudsen et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE -/- mouse model Diabetes & Vascular Disease Research 8 2011 117 124
18. J.P. Gutzwiller, S. Tschopp, A. Bock, C.E. Zehnder, A.R. Huber, and M. Kreyenbuehl et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men Journal of Clinical Endocrinology and Metabolism 89 2004 3055 3061
19. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes New England Journal of Medicine 359 2008 1577 1589
20. M.T. Jensen, J.L. Marott, K.H. Allin, B.G. Nordestgaard, and G.B. Jensen Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: The Copenhagen City Heart Study European Journal of Preventive Cardiology 19 2012 102 108
21. Cholesterol Treatment Trialists' (CTT) Collaborators P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, and R. Peto et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis Lancet 371 2008 117 125
22. M. Kim, M.J. Platt, T. Shibasaki, S.E. Quaggin, P.H. Backx, and S. Seino et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure Nature Medicine 19 2013 567 575
23. Lyxumia (lixisenatide) Summary of product characteristics Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002445/WC500140401.pdf 2013 [accessed 8 Aug 2013]
24. M. Marre, J. Shaw, M. Brandle, W.M. Bebakar, N.A. Kamaruddin, and J. Strand et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabetic Medicine 26 2009 268 278
25. S.P. Marso, J.B. Lindsey, J.M. Stolker, J.A. House, G. Martinez Ravn, and K.F. Kennedy et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies Diabetes & Vascular Disease Research 8 2011 237 240
26. Mount Sinai Hospital Blood pressure outcomes with liraglutide therapy (BOLT) Available at: http://clinicaltrials.gov/ct2/show/NCT01755572 2013 [accessed 8 Aug 2013]
27. M. Nauck, A. Frid, K. Hermansen, N.S. Shah, T. Tankova, and I.H. Mitha et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study Diabetes Care 32 2009 84 90
28. Novo Nordisk Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A long term evaluation (LEADER) Available at: http://clinicaltrials.gov/show/NCT01179048 2013 [accessed 8 Aug 2013]
29. Novo Nordisk Trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (SUSTAIN™ 6) Available at: http://clinicaltrials.gov/ct2/show/NCT01720446 2013 [accessed 8 Aug 2013]
30. T. Okerson, P. Yan, A. Stonehouse, and R. Brodows Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes American Journal of Hypertension 23 2010 334 339
31. T.G. Pickering, J.E. Hall, L.J. Appel, B.E. Falkner, J. Graves, and M.N. Hill et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research Circulation 111 2005 697 716
32. C. Pyke, and L.B. Knudsen The glucagon-like peptide-1 receptor - or not? Endocrinology 154 2013 4 8
33. L.E. Robinson, T.A. Holt, K. Rees, H.S. Randeva, and J.P. O'Hare Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis BMJ Open 2013 3
34. P. Rossing Time course of the blood pressure lowering effect of liraglutide therapy in type 2 diabetes (Liratime) Available at: http://clinicaltrials.gov/ct2/show/NCT01499108 2013 [accessed 8 Aug 2013]
35. D. Russell-Jones, A. Vaag, O. Schmitz, B.K. Sethi, N. Lalic, and S. Antic et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): A randomised controlled trial Diabetologia 52 2009 2046 2055
36. L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, and M.J. de Boer et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) European Heart Journal 28 2007 88 136
37. Sanofi Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (lixisenatide) (ELIXA) Available at: http://clinicaltrials.gov/show/NCT01147250 2013 [accessed 8 Aug 2013]
38. S.C. Thomson, A. Kashkouli, and P. Singh Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat American Journal of Physiology. Renal Physiology 304 2013 F137 F144
39. J.J. Torre, Z.T. Bloomgarden, R.A. Dickey, M.J. Hogan, J.J. Janick, and S.G. Jyothinagaram et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension Endocrine Practice 12 2006 193 222
40. F. Turnbull, B. Neal, C. Algert, J. Chalmers, N. Chapman, and J. Cutler et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials Archives of Internal Medicine 165 2005 1410 1419
41. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group BMJ 317 1998 703 713
42. Victoza (liraglutide) Prescribing information highlights. FDA Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022341s020lbl.pdf 2013 accessed 8 Aug 2013[]
43. Victoza (liraglutide) summary of product characteristics Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001026/WC500050017.pdf 2012 [accessed 8 Aug 2013]
44. T. Vilsbøll, M. Christensen, A.E. Junker, F.K. Knop, and L.L. Gluud Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials BMJ 344 2012 d7771
45. B. Wang, J. Zhong, H. Lin, Z. Zhao, Z. Yan, and H. He et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials Diabetes, Obesity & Metabolism 15 2013 737 749
46. Y. Wei, and S. Mojsov Tissue-specific expression of the human receptor for glucagon-like peptide-I: Brain, heart and pancreatic forms have the same deduced amino acid sequences FEBS Letters 358 1995 219 224
47. World Medical Association General Assembly World Medical Association Declaration of Helsinki - ethical principles for medical research involving human subjects Available at: http://www.wma.net/en/30publications/10policies/b3/ 2008 [accessed 8 Aug 2013]
48. B. Zinman, J. Gerich, J.B. Buse, A. Lewin, S. Schwartz, and P. Raskin et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) Diabetes Care 32 2009 1224 1230